Go Pro
OTCMKTS:BICX

Biocorrx Q3 2025 Earnings Report

Biocorrx logo
$0.23 -0.01 (-5.13%)
As of 08/19/2026 09:30 AM Eastern

Biocorrx EPS Results

Actual EPS
-$0.11
Consensus EPS
-$0.06
Beat/Miss
Missed by -$0.05
One Year Ago EPS
N/A

Biocorrx Revenue Results

Actual Revenue
$0.63 million
Expected Revenue
$0.19 million
Beat/Miss
Beat by +$440.00 thousand
YoY Revenue Growth
N/A

Biocorrx Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Biocorrx Earnings Headlines

Biocorrx Inc. (OTCMKTS:BICX) Short Interest Update
BioCorRx Inc.
Buy These Stocks Before August 31st
Keith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwide. The analyst, who called the 2020 crash early, is working with a former NSA codebreaker and Pentagon insider on a new approach to AI stocks ahead of August 31. Investors like Stephen and Keith W. say the tools helped shape their portfolios, though results vary and are not typical.tc pixel
See More Biocorrx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biocorrx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biocorrx and other key companies, straight to your email.

About Biocorrx

Biocorrx (OTCMKTS:BICX), through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.

View Biocorrx Profile